A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer
A phase 1/2 trial of SHR-A2102, Adebrelimab, Cetuximab in head and neck squamous cell carcinoma, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.
Overview
A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer is a phase 1/2 interventional study registered as NCT07059221 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 210 participants planned, started 2025-07-11 and due to reach its primary completion in 2027-03. Interventions recorded: SHR-A2102, Adebrelimab, Cetuximab, SHR-9839(sc), Carboplatin / Cisplatin. Conditions listed: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour
Shares SHR-A2102, Adebrelimab, Cetuximab, Jiangsu Hengrui Pharmaceuticals.
- TrialA Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin.
- TrialA Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin.
- TrialA Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin.
- TrialA Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Shares Adebrelimab, Cetuximab, Jiangsu Hengrui Pharmaceuticals, Cisplatin.
- TrialClinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals.
- TrialA Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin, Carboplatin.
- TrialA Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Carboplatin.